The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis
JJ Carlson, JA Roth - Breast cancer research and treatment, 2013 - Springer
The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT)
treatment decisions has been evaluated in many previous studies. However, it can be …
treatment decisions has been evaluated in many previous studies. However, it can be …
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
TP McVeigh, MJ Kerin - Breast Cancer: Targets and Therapy, 2017 - Taylor & Francis
Implementation of the Oncotype DX assay has led to a change in the manner in which
chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node …
chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node …
Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
Abstract Background The Oncotype DX breast recurrence score has been introduced more
than a decade ago to aid physicians in determining the need for systemic adjuvant …
than a decade ago to aid physicians in determining the need for systemic adjuvant …
[HTML][HTML] Short-chain fatty acids production by Bifidobacterium species in the presence of salep
B Usta-Gorgun, L Yilmaz-Ersan - Electronic Journal of Biotechnology, 2020 - Elsevier
Background Salep is obtained by grinding dried orchid tubers and used as a valuable
ingredient in the food industry. Because of the glucomannan content of salep, it is thought to …
ingredient in the food industry. Because of the glucomannan content of salep, it is thought to …
Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in …
MC Roberts, DP Miller, S Shak, VI Petkov - Breast cancer research and …, 2017 - Springer
Abstract Purpose The Oncotype DX® Breast Recurrence Score™(RS) assay is validated to
predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients …
predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients …
[HTML][HTML] Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision …
J Albanell, A Gonzalez, M Ruiz-Borrego, E Alba… - Annals of …, 2012 - Elsevier
Background This study examined the impact of the Recurrence Score (RS) in Spanish
breast cancer patients and explored the associations between clinicopathological markers …
breast cancer patients and explored the associations between clinicopathological markers …
Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review …
Gene expression profiling and expanded immunohistochemistry tests to guide the use of
adjuvant chemotherapy in breast cancer man Page 1 DOI 10.3310/hta17440 HealtH tecHnology …
adjuvant chemotherapy in breast cancer man Page 1 DOI 10.3310/hta17440 HealtH tecHnology …
A comparison of landmark methods and time-dependent ROC methods to evaluate the time-varying performance of prognostic markers for survival outcomes
A Bansal, PJ Heagerty - Diagnostic and prognostic research, 2019 - Springer
Background Prognostic markers use an individual's characteristics at a given time to predict
future disease events, with the ultimate goal of guiding medical decision-making. If an …
future disease events, with the ultimate goal of guiding medical decision-making. If an …
[HTML][HTML] Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information
LP Feeley, AM Mulligan, D Pinnaduwage, SB Bull… - Modern Pathology, 2014 - Elsevier
The objectives of this study were to determine the prognostic significance of subgrouping
estrogen receptor (ER)-positive breast tumors into low-and high-risk luminal categories …
estrogen receptor (ER)-positive breast tumors into low-and high-risk luminal categories …
Economic implications of 21‐gene breast cancer risk assay from the perspective of an Israeli‐managed health‐care organization
SH Klang, A Hammerman, N Liebermann… - Value in …, 2010 - Wiley Online Library
ABSTRACT Objective: Oncotype DX, a 21‐gene assay, was clinically validated as a
predictor of 10‐year recurrence‐free survival and treatment response in patients with early …
predictor of 10‐year recurrence‐free survival and treatment response in patients with early …